These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. To switch (statins) or not to switch? That is the question. Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP Expert Opin Pharmacother; 2010 Dec; 11(18):2943-6. PubMed ID: 20958109 [TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. Comparative effectiveness of generic and brand-name statins on patient outcomes. Ann Intern Med; 2014 Sep; 161(6):I-30. PubMed ID: 25222407 [No Abstract] [Full Text] [Related]
4. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076 [TBL] [Abstract][Full Text] [Related]
5. Compliance after switching from branded to generic statins. Romanelli RJ; Jukes T; Segal JB Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387 [TBL] [Abstract][Full Text] [Related]
8. Clinical review: impact of statin substitution policies on patient outcomes. Atar D; Carmena R; Clemmensen P; K-Laflamme A; Wassmann S; Lansberg P; Hobbs R Ann Med; 2009; 41(4):242-56. PubMed ID: 19191052 [TBL] [Abstract][Full Text] [Related]
9. The paradigm of stains: will the lower cost of generics translate into health gains? Seabra-Gomes R Rev Port Cardiol; 2007 May; 26(5):497-501. PubMed ID: 17691276 [No Abstract] [Full Text] [Related]
11. Patient co-payment and adherence to statins: a review and case studies. Simoens S; Sinnaeve PR Cardiovasc Drugs Ther; 2014 Feb; 28(1):99-109. PubMed ID: 24150747 [TBL] [Abstract][Full Text] [Related]
12. The impact of generic reference pricing interventions in the statin market. Puig-Junoy J Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619 [TBL] [Abstract][Full Text] [Related]
13. Zero copayment for generic statins could save billions. Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806 [No Abstract] [Full Text] [Related]
14. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736 [TBL] [Abstract][Full Text] [Related]
15. [Adherence to statins: updates and practical proposals]. Bauwens M; Schneider MP; Nanchen D Rev Med Suisse; 2016 Mar; 12(508):445-8, 450. PubMed ID: 27089601 [TBL] [Abstract][Full Text] [Related]
16. Capsule commentary on Romanelli et al., predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries. Pathak H J Gen Intern Med; 2014 Oct; 29(10):1391. PubMed ID: 25103124 [No Abstract] [Full Text] [Related]
18. When choosing statin therapy: the case for generics. Green JB; Ross JS; Jackevicius CA; Shah ND; Krumholz HM JAMA Intern Med; 2013 Feb; 173(3):229-32. PubMed ID: 23303273 [TBL] [Abstract][Full Text] [Related]
19. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Sedjo RL; Cox ER Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498 [TBL] [Abstract][Full Text] [Related]